Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS
申请人:Parker Hughes Institute located at Roseville, Minnesota
公开号:US20030181717A1
公开(公告)日:2003-09-25
Novel chiral derivitaves of non-nucleoside inhibitors (NNI), particularly R-isomers of halopyridyl and thiazoyl thiourea compounds are provided as potent inhibitors of reverse transcriptase (RT), and particularly of retroviral RT, most particularly HIV RT. The stereospecific compounds and compositions of the invention inhibit replication of retrovirus, particularly human immunodeficiency virus-1 (HIV-1) and drug resistant strains.
本发明提供了非核苷抑制剂(NNI)的新型手性衍生物,特别是卤代吡啶和噻唑酰基硫脲化合物的 R-异构体,作为逆转录酶(RT),特别是逆转录病毒 RT,尤其是 HIV RT 的强效抑制剂。本发明的立体特异性化合物和组合物可以抑制逆转录病毒的复制,特别是人类免疫缺陷病毒-1(HIV-1)和耐药株。
US6545152B1
申请人:——
公开号:US6545152B1
公开(公告)日:2003-04-08
Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS
作者:Bini Mathew、Pedro Ruiz、Shilpa Dutta、Jordan T. Entrekin、Sixue Zhang、Kaval D. Patel、Micah S. Simmons、Corinne E. Augelli-Szafran、Rita M. Cowell、Mark J. Suto